Skip to main content
Premium Trial:

Request an Annual Quote

Freenome Impact Advisory Board

Freenome has announced the creation of what it calls its Impact Advisory Board, a group tasked with helping the company optimize strategies, including those that will guide its first commercial launch of a blood-based, artificial intelligence-derived genomic test for the early detection of colorectal cancer.

The new board includes NDA Partners' Alberto Gutierrez, a former 25-year veteran of the US Food and Drug Administration, who will be tasked with guiding regulatory strategy. Joining Gutierrez are two experts on payor strategy: Louis Jacques, chief clinical officer of ADVI Health and former head of the Centers for Medicare and Medicaid Services' Coverage and Analysis Group; and Sherie Smalley, senior medical director of medical policy at UPMC Health Plan.

It also includes clinical development advisors with expertise in gastroenterology, including Douglas Robertson from the US Multi-Society Task Force of Colorectal Cancer.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.